Fatty liver disease
MONDO:0004790A reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis.
Also known as: fatty liver
577 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Kidney-Liver drug trial halted early – what happened?
Disease control TerminatedThis small Phase 2 study tested two doses of vonafexor, an oral drug, in 10 people with mild-to-moderate chronic kidney disease and suspected MASH (a type of fatty liver disease). The goal was to see if vonafexor could improve kidney function. However, the trial was terminated ea…
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental drug for cholesterol and fatty liver fails to advance
Disease control TerminatedThis early-stage trial tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and non-alcoholic fatty liver disease (NAFLD). The main goal was to check safety and how the body processes the drug. The study was terminated, meaning it stopped early, so it…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug hope for fatty liver in PCOS women?
Disease control TerminatedThis study tested a drug called saroglitazar in women with polycystic ovary syndrome (PCOS) who also have nonalcoholic fatty liver disease (NAFLD). The goal was to see if the drug could safely reduce liver fat over 24 weeks compared to a placebo. The trial was planned for 60 wome…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Fatty liver drug trial halted early: what we know
Disease control TerminatedThis early-stage study tested an experimental drug called FT-4101 in 14 overweight or obese adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat. The study was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Heart drug digoxin tested for alcoholic hepatitis – early trial halted
Disease control TerminatedThis small, early-phase study tested whether the heart medication digoxin could reduce inflammation in people with severe alcohol-associated hepatitis. 23 participants were randomly assigned to receive intravenous digoxin or no digoxin for up to 28 days. The trial was terminated …
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
Disease control TerminatedThis study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaning…
Phase: PHASE2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:33 UTC
-
Clinic ultrasound may catch fatty liver on the spot
Diagnosis TerminatedThis study is testing whether a simple ultrasound done right in the doctor's office can help diagnose fatty liver disease early. Researchers will compare the bedside scan results with standard radiology imaging in 500 patients. If it works, it could make diagnosis faster and more…
Sponsor: Medical College of Wisconsin • Aim: Diagnosis
Last updated Jul 15, 2026 00:00 UTC
-
Experimental drug aims to prevent bleeding veins in fatty liver disease
Prevention TerminatedThis study tested a drug called belapectin to see if it could prevent the formation of esophageal varices (enlarged veins in the esophagus) in people with NASH cirrhosis and signs of high blood pressure in the liver. The trial enrolled 357 adults and compared belapectin to a plac…
Phase: PHASE2, PHASE3 • Sponsor: Galectin Therapeutics Inc. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Sugar-Free diet may shield hispanic kids from fatty liver
Prevention TerminatedThis study tested whether a low-sugar diet could prevent non-alcoholic fatty liver disease (NAFLD) in Hispanic children ages 6 to 9 who were at higher risk. Over two years, researchers compared kids who followed the diet with those who ate normally. The goal was to see if cutting…
Phase: NA • Sponsor: Emory University • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
NASH registry study aims to map disease in chinese patients
Knowledge-focused TerminatedThis study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC